The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 7, Issue 3, Pages 269-289
Publisher
Future Science, LTD
Online
2015-04-01
DOI
10.4155/fmc.14.143
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2
- (2014) James F. Blake et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response
- (2014) Elda Grabocka et al. CANCER CELL
- Prospects for MEK inhibitors for treating cancer
- (2014) Juan Martin-Liberal et al. Expert Opinion On Drug Safety
- Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
- (2014) Matteo S. Carlino et al. Molecular Oncology
- Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors
- (2014) Martin L. Sos et al. Cell Reports
- Extracellular signal-regulated kinase-5: Novel mediator of insulin and tumor necrosis factor α-stimulated vascular cell adhesion molecule-1 expression in vascular cells 细胞外信号调节激酶-5:一种新的调节胰岛素与肿瘤坏死因子α刺激下的血管细胞上的血管细胞粘附分子-1表达的介质
- (2014) Daniel Z. Mackesy et al. Journal of Diabetes
- Kinase Drug Discovery – What’s Next in the Field?
- (2013) Philip Cohen et al. ACS Chemical Biology
- Inhibitors of protein kinases
- (2013) David Shugar et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
- (2013) Patrick A. Ott et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors
- (2013) K. J. Basile et al. CANCER RESEARCH
- RSK Isoforms in Cancer Cell Invasion and Metastasis
- (2013) F. J. Sulzmaier et al. CANCER RESEARCH
- ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition
- (2013) J. M. Buonato et al. CANCER RESEARCH
- C-RAF Mutations Confer Resistance to RAF Inhibitors
- (2013) R. Antony et al. CANCER RESEARCH
- Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
- (2013) H. K. Bid et al. CLINICAL CANCER RESEARCH
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- B-Raf mutation: A key player in molecular biology of cancer
- (2013) M.A. Rahman et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Requirement of B-Raf, C-Raf, and A-Raf for the growth and survival of mouse embryonic stem cells
- (2013) Wenjing Guo et al. EXPERIMENTAL CELL RESEARCH
- p38-Mediated phosphorylation of Eps15 endocytic adaptor protein
- (2013) Yue Zhou et al. FEBS LETTERS
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- Mitogen-Activated Protein (MAP) Kinase Scaffolding Proteins: A Recount
- (2013) Melanie Meister et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines
- (2013) S. Radtke et al. JOURNAL OF CELL SCIENCE
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Melanoma combination therapies ward off tumor resistance
- (2013) Ken Garber NATURE BIOTECHNOLOGY
- IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors
- (2013) Katherine L Jameson et al. NATURE MEDICINE
- Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer
- (2013) Darrin D Stuart et al. NATURE MEDICINE
- Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
- (2013) J. J. Luke et al. ONCOLOGIST
- MEK in cancer and cancer therapy
- (2013) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- ERK5 Activation by Gq-Coupled Muscarinic Receptors Is Independent of Receptor Internalization and β-Arrestin Recruitment
- (2013) Guzmán Sánchez-Fernández et al. PLoS One
- Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
- (2013) A. J. Sievert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ERK Pathway Inhibitors: How Low Should We Go?
- (2013) M. H. Nissan et al. Cancer Discovery
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells
- (2012) Jean-Philippe Guégan et al. CARCINOGENESIS
- Discovery of Potent and Selective Covalent Inhibitors of JNK
- (2012) Tinghu Zhang et al. CHEMISTRY & BIOLOGY
- Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
- (2012) H. Wong et al. CLINICAL CANCER RESEARCH
- Whole-Genome Sequencing in Personalized Therapeutics
- (2012) P Cordero et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- MAP kinase signalling cascades and transcriptional regulation
- (2012) Shen-Hsi Yang et al. GENE
- RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
- (2012) Antonio Garcia-Gomez et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Specifically targeting ERK1 or ERK2 kills Melanoma cells
- (2012) Jianzhong Qin et al. Journal of Translational Medicine
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Personalized oncology: Recent advances and future challenges
- (2012) Madhu Kalia METABOLISM-CLINICAL AND EXPERIMENTAL
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Mammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update
- (2012) John M. Kyriakis et al. PHYSIOLOGICAL REVIEWS
- A rare point mutation in the Ras oncogene in hepatocellular carcinoma
- (2012) Akinobu Taketomi et al. SURGERY TODAY
- Approaches to discover non-ATP site kinase inhibitors
- (2012) Lori Krim Gavrin et al. MedChemComm
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- DUSPs, to MAP kinases and beyond
- (2012) Ching-Yu Huang et al. Cell and Bioscience
- MEK1/2 dual-specificity protein kinases: Structure and regulation
- (2011) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Norathyriol Suppresses Skin Cancers Induced by Solar Ultraviolet Radiation by Targeting ERK Kinases
- (2011) J. Li et al. CANCER RESEARCH
- Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
- (2011) F. Su et al. CANCER RESEARCH
- Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation
- (2011) H. Wang et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Total ERK1/2 activity regulates cell proliferation
- (2011) Renaud Lefloch et al. CELL CYCLE
- Signal control through Raf: in sickness and in health
- (2011) Jihan K Osborne et al. CELL RESEARCH
- MAPK pathway activation in pilocytic astrocytoma
- (2011) David T. W. Jones et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Challenges ahead in signal transduction: MAPK as an example
- (2011) Christina Kiel et al. CURRENT OPINION IN BIOTECHNOLOGY
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
- (2011) Bert H. O'Neil et al. JOURNAL OF CLINICAL ONCOLOGY
- Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
- (2011) R. Fritsche-Guenther et al. Molecular Systems Biology
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Resistance to BRAF Inhibition in Melanomas
- (2011) David B. Solit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- Resistance to MEK Inhibitors: Should We Co-Target Upstream?
- (2011) P. I. Poulikakos et al. Science Signaling
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Small-Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics
- (2010) Jeremy L. Yap et al. ChemMedChem
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Emerging MEK inhibitors
- (2010) James A McCubrey et al. EXPERT OPINION ON EMERGING DRUGS
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
- (2010) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan
- (2010) Masatoshi Kudo et al. ONCOLOGY
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
- (2009) Kathryn Balmanno et al. INTERNATIONAL JOURNAL OF CANCER
- Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway
- (2009) S.-Y. Shin et al. JOURNAL OF CELL SCIENCE
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control
- (2009) Alex M. Aronov et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
- (2009) D. A. Ritt et al. MOLECULAR AND CELLULAR BIOLOGY
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- The N-Terminal Domain of ERK1 Accounts for the Functional Differences with ERK2
- (2008) Matilde Marchi et al. PLoS One
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started